ASND · NASDAQ · STOCK
Ascendis Pharma A/S (ASND) Stock Analysis
$270.67
52W $186.05 – $282.15
58/100
$16.80B
19.2
0.38
⚠
Buy rating, but near-term risk/reward is unfavorable
The long-term recommendation is based on the composite investment score. The near-term risk/reward is based on nearby support and resistance levels. These can differ when a strong company trades close to resistance with support further below.
Is ASND Bullish or Bearish?
Bullish.
Innellis AI committee rates Ascendis Pharma A/S (ASND) Buy with a composite score of 58/100
, based on 6 analysts with 67% agreement.
Last updated September 06, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +16.90 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -3.10 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Risk Analyst remains cautious — high leverage (debt-to-equity 1.93) amplifies downside in a stress scenario. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- ROE of 86.9% shows genuine earnings power backing the valuation — Value
- Revenue growing 113.3% YoY -- genuine top-line momentum — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- Price-to-book of 22.3x prices in significant intangible value — Value
- Debt-to-equity of 1.93 adds balance-sheet risk to the value case — Value
- 4 consecutive earnings misses -- execution concerns — Growth
- RSI at 72 is in overbought territory — Technical
- High leverage (debt-to-equity 1.93) amplifies downside in a stress scenario — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of September 06, 2026
Overall Committee Score
58/100
Agreement
67%
Analysts
6
Conviction
Contested
Sector Rank
Top 68%
of 192 Healthcare peers
Value Analyst
neutral
50
/ 100 · High confidence
Fair value -- neither a bargain nor obviously overpriced
+ ROE of 86.9% shows genuine earnings power backing the valuation
− Price-to-book of 22.3x prices in significant intangible value
Growth Analyst
bullish
63
/ 100 · High confidence
Strong, accelerating growth with consistent execution
+ Revenue growing 113.3% YoY -- genuine top-line momentum
− 4 consecutive earnings misses -- execution concerns
Technical Analyst
bullish
61
/ 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
− RSI at 72 is in overbought territory
Risk Analyst
bearish
30
/ 100 · Low confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− High leverage (debt-to-equity 1.93) amplifies downside in a stress scenario
Macro Analyst
bullish
80
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst
bullish
64
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.20 across 29 articles, 14d)
Portfolio Manager
neutral
45
/ 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2704.43)
Investment Thesis Evolution
Committee score moved marginally from 58.1 to 58.1.
Comparing 2026-09-05 to 2026-09-06 (1 day apart).
Technical Analysis
RSI (14)
72.3
Overbought
MACD Histogram
2.219
Bullish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Hh Hl
Support
$239.93
Resistance
$281.73
Bollinger %B
1.00
Inside Bands
Price vs Moving Averages
EMA 9
$262.21
Above
EMA 21
$257.45
Above
EMA 50
$252.91
Above
EMA 200
$232.13
Above
Fundamental Analysis
Valuation
61
Growth
55
Profitability
75
Financial Health
100
Cash Flow
70
Valuation
P/E Ratio
19.2×
P/B Ratio
10.44×
PEG Ratio
0.03
Dividend Yield
0.00%
52W High
$282.15
52W Low
$186.05
Quality & Growth
ROE
13458.2%
ROA
-1682.3%
Gross Margin
9018.6%
Operating Margin
1038.1%
Revenue Growth YoY
—
Debt / Equity
0.31
AI Fundamental Assessment
P/E ratio of 19.2 (inexpensive relative to a 15-40x range); Price-to-book of 10.4x; PEG ratio of 0.0 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 134.6%; Return on assets of -16.8%; Net margin of 71.7%; Gross margin of 90.2%; Current ratio of 2.99 (healthy short-term liquidity); Debt-to-equity of 0.31; Free cash flow per share is positive (5.24); Most recent quarter missed estimates by 48.9%; 4 consecutive earnings misses; EPS growth accelerating (-40.0% -> +193.5% QoQ); Average YoY EPS growth of 212.5%; Analyst estimates rising over recent quarters
Get the Full ASND Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →